Background: Advanced cirrhosis is a state marked by synthetic and vascular decompensation, rise in splanchnic blood volume, hyper-dynamic condition with, systemic vasodilatation, AKI is one of the side-effects of cirrhosis, happening in about 45% of hospital stayed cases, and was accompanying with higher death. This study aimed to evaluate co-peptin versus VCAM-1 as a biomarker for early detection of HRS-AKI in decompensated cirrhotic patients.
Aim: to compare between co-peptin versus VCAM-1 as a biomarker for early detection of HRS-AKI in decompensated cirrhotic patients.
Patients and Methods: This study was conducted between January 2020 and June 2021, on 80 patients attending to Al-Azhar University Assuit branch, Egypt during the time of the study. This work included three groups: Control Group (I): (15 Patients) age and sex-matching controls, Group (II): 40 cases with liver cirrhosis without AKI and Group (III): 40 liver cirrhosis patients with AKI. The study included patient 40 cases with liver cirrhosis without AKI and 40 liver cirrhosis patients with AKI
Results: A high significantly positive association among VCAM -1 and Co-peptin in group (A) was observed (Pvalue<0.001), additionally, there was a significantly positive correlation among VCAM -1 and co-peptin in group (B),(P=0.027), lastly, there non-significant correlation between VCAM -1 and co-peptin in group C (p=0.315)
Conclusion: Cases with de-compensated liver cirrhosis and HRS-AKI have marked increase in co-peptin, VCAM-1in comparison with cases with decompensated cirrhosis with no HRS.